Focus on launch metrics (prescriptions, patient starts) and payer coverage for the new indication. The existing commercial presence for MDD may accelerate uptake. Monitor competitor activity in Alzheimer's agitation (e.g., brexpiprazole). Revenue guidance updates in upcoming earnings will be key.
Price Chart
Executive Summary
Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agitation associated with dementia due to Alzheimer's disease, a second indication for the drug. The approval, granted under Priority Review with Breakthrough Therapy designation, addresses a large unmet need affecting up to 76% of the 7+ million Alzheimer's patients in the U.S. This label expansion significantly expands AUVELITY's commercial opportunity beyond its existing major depressive disorder indication.
Key Facts
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026
- Approval based on Phase 3 ADVANCE-1 and ACCORD-2 studies showing statistically significant improvement in agitation symptoms and longer time to relapse
- Alzheimer's disease affects >7 million Americans; agitation reported in up to 76% of patients
- AUVELITY already approved for major depressive disorder (2022) with >300,000 patients exposed and commercial infrastructure in place
- Patent protection extends to at least 2043
Financial Impact
Approval opens a large new market: up to ~5.3 million Alzheimer's patients with agitation. AUVELITY's existing MDD revenue was $X (not disclosed); this indication could materially accelerate revenue growth.
Risk Factors
- Boxed warning for suicidal thoughts and behaviors may limit use in elderly patients
- Competition from other treatments for Alzheimer's agitation (e.g., brexpiprazole) and off-label antipsychotics
- Reimbursement and pricing dynamics could slow adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285345 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.95 (−17.57%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.95 (−25.51%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.95 (−28.92%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.95 (−29.15%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.95 (−27.57%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.95 (−30.17%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access